Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. has achieved an exceptional Return on Invested Capital (ROIC) of 41.44%, significantly outperforming its Weighted Average Cost of Capital (WACC) of 5.78%. This indicates robust financial health and efficient operations, generating more than seven times the value for every dollar invested. The company's strong performance positions it as a leader in the healthcare intelligence sector, signaling a promising outlook for investors.
Definitive Healthcare Launches Turbo AI Healthcare Intelligence Platform
Definitive Healthcare (Nasdaq: DH) reported Q2 2026 revenue of $55.2 million, a 9% decrease year-over-year, but within guidance. The company's net loss improved, and it launched Turbo, an AI-powered healthcare intelligence platform. Definitive Healthcare also provided guidance for Q3 and full-year 2026, anticipating continued revenue and adjusted EBITDA in line with expectations, despite a negative market reaction to the Q2 earnings report.
Definitive Healthcare Q2 2026 slides: profit beats amid revenue decline
Definitive Healthcare (NASDAQ:DH) exceeded profitability guidance in Q2 2026 despite a 9% year-over-year revenue decline, driven by strong cost management. The company reported adjusted operating income and adjusted EBITDA above expectations, leading to a 3.08% rise in shares after hours. Definitive Healthcare also raised its full-year profit outlook while tightening revenue guidance, signaling confidence in its operational efficiency amidst market challenges.
Definitive Healthcare revenue falls 9% in Q2, cash flow holds
Definitive Healthcare reported a 9% revenue decline in Q2 2026, reaching $55.2 million, but maintained strong unlevered free cash flow of $11.6 million. Despite a fall in adjusted net income and EBITDA, the company highlighted strategic wins and the launch of its AI-powered platform, Turbo. Definitive Healthcare also provided full-year revenue guidance between $220.0 million and $222.0 million, emphasizing a focus on stabilizing profitability while investing in growth initiatives.
Form 8K Definitive Healthcare Corp For: 10 August By Investing.com
This article reports on Definitive Healthcare Corp's Form 8K filing for August 10th. The brief news item also notes a -7.85% drop in Definitive Healthcare's stock (DH) and was published by Investing.com.
Definitive Healthcare Corp. Q2 2026: Revenue $55.2M, EPS $(0.05) — 10-Q Summary
Definitive Healthcare Corp. reported Q2 2026 results, showing revenue of $55.2M, a 9% year-over-year decline, and a narrowed net loss of $(5.4)M, with EPS at $(0.05). The company experienced customer churn, particularly among smaller accounts, and initiated a restructuring plan to cut costs. They also launched an AI-powered platform pilot and addressed claims data source disruptions.
Definitive Healthcare (DH) books $197M goodwill hit and faces Nasdaq bid-price risk
Definitive Healthcare (DH) reported a significant net loss of $199.8 million for the six months ended June 30, 2026, primarily due to a non-cash $197.2 million goodwill impairment charge following sustained stock price declines. The company also received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day remediation period. Despite these challenges, DH maintained positive operating cash flow and a strong cash position, while also implementing a restructuring plan and resolving an acquisition earnout dispute.
Form 8K Definitive Healthcare Corp For: 10 August By Investing.com
This article announces that Definitive Healthcare Corp has filed a Form 8K on August 10. The filing is provided by Investing.com, a financial markets news source. The content primarily consists of the announcement itself and includes stock market data and other news headlines from Investing.com.
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Definitive Healthcare (Nasdaq: DH) reported its second-quarter 2026 financial results, with revenue of $55.2 million, a 9% decrease year-over-year, but profits surpassing expectations. The company highlighted improvements in net dollar retention and the launch of its AI-powered healthcare intelligence platform, Turbo. Definitive Healthcare also provided financial guidance for the third quarter and full year 2026, anticipating continued growth and profitability.
Definitive Healthcare (Nasdaq: DH) Q2 2026 revenue hits $55.2M amid large write-down
Definitive Healthcare (Nasdaq: DH) reported Q2 2026 revenue of $55.2 million, a decrease from Q2 2025, and a GAAP net loss of $7.5 million. The company incurred a significant goodwill impairment charge of $197.2 million for the first half of 2026, leading to a year-to-date net loss of $199.8 million. Despite declining top-line and adjusted earnings, the company highlighted strong operating cash flow and improved net dollar retention, while also providing guidance for Q3 and full-year 2026.
Definitive Healthcare Launches Early Adopter Program for New AI-Powered Healthcare Intelligence Platform
Definitive Healthcare (Nasdaq: DH) has announced an early adopter program for its new AI-powered healthcare intelligence platform, providing select organizations with early access. The platform integrates claims, provider, consumer, and expert data with conversational AI to surface insights, optimize market opportunities, and improve decision-making. The company aims for general availability later in 2026, incorporating feedback from participants spanning health systems, life sciences, and other healthcare-selling industries.
Definitive Healthcare Corp. (DH) chair has 12,166 shares withheld for tax
Definitive Healthcare Corp.'s Executive Chairman and 10% owner, Jason Ronald Krantz, had 12,166 Class A common shares withheld on August 1, 2026, to cover tax obligations from the vesting of Restricted Stock Units (RSUs) at a price of $0.6823 per share. Following this transaction, Krantz directly holds 1,189,272 Class A shares and indirectly owns 450,000 shares through DH Holdings. This disposition was for tax purposes and not an open-market sale.
Definitive Healthcare (DH) CFO has 1,881 shares withheld to cover RSU taxes
Definitive Healthcare Corp. reported that its Chief Financial Officer, Casey Heller, had 1,881 shares of Class A Common Stock withheld on August 1, 2026. This action was taken to satisfy tax withholding obligations related to the vesting of previously reported Restricted Stock Units (RSUs). Following this transaction, Heller directly holds 1,839,595 shares of the company's stock.
Definitive Healthcare to report Q2 2026 earnings on August 10 with a live webcast and call.
Definitive Healthcare Corp. announced it will release its second-quarter financial results for the period ending June 30, 2026, on August 10, after the market closes. The company will host a conference call and webcast at 5:00 PM ET to discuss these results, which will be accessible via their investor relations website. A replay of the event will be available until September 9, 2026, providing investors with an opportunity to review the company's performance and outlook.
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. announced it will report its second quarter 2026 financial results on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results. Interested parties can access the live audio webcast through the company's Investor Relations website or
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. (Nasdaq: DH) announced it will release its second-quarter financial results for 2026 on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss these results. A replay of the call will be available until September 9, 2026.
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare Corp. (Nasdaq: DH) announced inducement awards granted to Srinivas Attipalli, the new SVP and Head of AI & Data - Product. Mr. Attipalli received 1,063,830 time-based restricted stock units (RSUs), effective July 24, 2026, as an inducement to his employment. These RSUs will vest over time, starting June 1, 2027, in accordance with the company's 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Definitive Healthcare Corp. Announces Appointment of Srinivas Attipalli as Head of Ai & Data - Product
Definitive Healthcare Corp. announced the appointment of Srinivas Attipalli as Head of AI & Data - Product. The company, which specializes in healthcare commercial intelligence, uses AI and machine learning to transform data into insights. This new appointment is expected to further enhance their data platform and analytical capabilities.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of "Reduce" from Brokerages
Nine brokerages have assigned Definitive Healthcare Corp. (NASDAQ:DH) an average "Reduce" rating, with a consensus 12-month price target of $2.47 across analysts actively covering the stock. The company's shares opened at $0.68, significantly below its 52-week high, while institutional investors hold a substantial 98.67% of its stock. Definitive Healthcare recently reported strong quarterly earnings, surpassing analyst estimates for both adjusted EPS and revenue.
Definitive Healthcare (NASDAQ:DH) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Definitive Healthcare (NASDAQ:DH) from "hold" to "buy," despite a cautious broader analyst view with an average rating of "Reduce" and a target price of $2.47. The stock is trading near its 52-week low at $0.68, with a market capitalization of $72.1 million. Definitive Healthcare recently exceeded earnings and revenue expectations in its latest quarter and provided Q2 and full-year 2026 guidance.
DH|Definitive Healthcare Corp|Price:0.677|Chg%:-0.008
Definitive Healthcare Corp (DH) is currently trading at $0.683, down 0.42%. Despite healthy fundamentals and high growth potential, its stock price has seen significant declines over the past year. Analysts mostly rate the stock as "Hold" with a target price of $2.20, indicating a potential upside of over 200%.
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and MindWalk Holdings (HYFT)
Analysts have provided optimistic outlooks for healthcare companies Quest Diagnostics (DGX) and MindWalk Holdings (HYFT). Quest Diagnostics received a Buy rating from William Blair with a $231.40 average price target, while MindWalk Holdings also secured a Buy rating from JonesTrading and H.C. Wainwright, with a $5.00 price target, suggesting a significant upside. Both companies are viewed positively by analysts in the Healthcare sector.
[Form 4] Definitive Healthcare Corp. Insider Trading Activity
Definitive Healthcare Corp.'s Chief Legal Officer, Jonathan Paris, had 30,591 shares of Class A Common Stock withheld at $0.80 per share to cover tax obligations related to vested Restricted Stock Units (RSUs). Following this transaction, Paris directly holds 872,263 shares of Class A Common Stock. The filing, categorized as "Neutral" in impact and sentiment, details this non-market tax-withholding disposition.
Definitive Healthcare (DH) CEO has shares withheld to cover RSU taxes
Definitive Healthcare Corp. CEO Kevin Coop reported a tax-related share disposition. The company withheld 37,593 shares of Class A common stock at $0.80 per share to cover Coop’s tax withholding obligations upon the settlement of restricted stock units (RSUs). This transaction was not an open-market sale, and following the withholding, Coop directly owns 4,975,229 shares of Class A common stock.
July 2026's Spotlight On Promising Penny Stocks
This article highlights three promising penny stocks for July 2026: Definitive Healthcare (DH), PMV Pharmaceuticals (PMVP), and Granite Point Mortgage Trust (GPMT). Each company is analyzed based on its financial health, market capitalization, operational specifics, and potential for growth, despite the inherent risks associated with penny stocks. The piece emphasizes the importance of robust financials and a clear growth path when considering such investments.
Definitive Healthcare Corp.(NasdaqGS:DH) added to Russell Microcap Value Benchmark Index
Definitive Healthcare Corp. (NasdaqGS:DH) has been added to the Russell Microcap Value Benchmark Index. This news comes alongside other recent developments for the company, including being dropped from the Russell 2000 Value Benchmark and Russell 2000 Dynamic Index,
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 2000 Value Benchmark
Definitive Healthcare Corp. (NasdaqGS: DH) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other index changes for the company, including being added to the Russell Microcap Value Benchmark Index and dropped from various Russell 2000 and 3000 indices. The company, which provides healthcare commercial intelligence through its SaaS platform, recently saw its price target cut by BofA due to intensifying competitive pressures.
Why is Definitive Healthcare stock climbing today? By Investing.com
Definitive Healthcare Corp (DH) stock surprisingly climbed 5.1% in after-hours trading despite a dramatic double downgrade from BofA Securities, which cited concerns over commoditization and AI in the healthcare data market. The bounce appears to be a technical relief rally, as the stock hit a 52-week low and BofA's new price target, while pessimistic, was marginally above the after-hours price, potentially clearing an overhang of uncertainty.
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 3000 Index
Definitive Healthcare Corp. (NasdaqGS: DH) has been dropped from the Russell 3000 Index, as well as several other Russell indices including the Russell 2000 and Russell 2500 Value Benchmarks. Concurrently, the company was added to the Russell Microcap Value Benchmark Index and the Russell Microcap Index. This follows a period where the company's shares experienced a significant drop, and analysts like BofA downgraded the stock due to intensifying competitive pressures.
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 2500 Index
Definitive Healthcare Corp. (NasdaqGS: DH) has been removed from the Russell 2500 Index, as announced on June 28, 2026. This follows a series of other re-indexings, including its addition to the Russell Microcap Value Benchmark Index and removal from several other Russell indices on June 29, 2026. The company, which provides healthcare commercial intelligence, also saw a downgrade from BofA due to rising competitive pressures.
Definitive Healthcare Corp. Class A Actuals & Estimates (NASDAQ:DH)
This article provides an overview of Definitive Healthcare Corp. (NASDAQ: DH) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, upcoming earnings dates, and current financial metrics like revenue, net income, and EBITDA.
Definitive Healthcare (NASDAQ: DH) warned by Nasdaq on sub-$1 bid price
Definitive Healthcare (NASDAQ: DH) has received a notice from Nasdaq for failing to meet the minimum $1.00 per share bid price requirement. The company's stock traded below this threshold for 30 consecutive business days, from May 6, 2026, to June 17, 2026. Definitive Healthcare has 180 calendar days, until December 15, 2026, to regain compliance, potentially through actions like a reverse stock split.
Restaurant365 Names Kate Hastings Chief Customer Officer as It Expands Investment in Customer Success
Restaurant365, a leading restaurant management platform, has appointed Kate Hastings as its Chief Customer Officer to enhance customer success and help operators maximize the value of their investment. Hastings, with over 15 years of experience, will oversee all post-sale customer functions, focusing on helping restaurants navigate increasing complexities like rising food costs and profitability management. Her appointment underscores Restaurant365's commitment to enabling customers to translate insights into actionable results and improve their business outcomes.
Definitive Healthcare (Nasdaq:DH) - Stock Analysis
This Simply Wall St analysis provides an overview of Definitive Healthcare (Nasdaq:DH), highlighting that it's trading significantly below its estimated fair value with projected strong earnings growth. Despite its volatile share price history and current unprofitability, analysts have recently raised price targets, citing improved profitability assumptions and product enhancements. The article also details recent product updates, including expanded data coverage and new integrations, alongside past financial performance and analyst sentiment.
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV) and Tectonic Therapeutic (TECX)
This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV), and Tectonic Therapeutic (TECX). Barclays and Piper Sandler maintained Buy ratings for Amneal, projecting a 17.2% upside. Elevance Health also received a Buy rating from Barclays and Bernstein, despite a slight projected downside. Tectonic Therapeutic, supported by Wells Fargo and Raymond James with Buy ratings, shows a significant implied upside of 188.8%.
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)
Analysts have provided new ratings for several healthcare companies. Bank of America Securities maintained a Buy rating for Omnicell (OMCL) with a $70.00 price target, while Wells Fargo maintained a Buy rating for Oric Pharmaceuticals (ORIC) with a $25.00 price target. Wells Fargo also maintained a Hold rating for Pfizer (PFE) with a $28.00 price target, noting its proximity to a 52-week low.
Director Hamood receives 189K RSUs at Definitive Healthcare (DH)
Definitive Healthcare director Samuel A. Hamood was granted 189,190 restricted stock units (RSUs) of Class A Common Stock at no cash cost. These RSUs are set to vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting, contingent on his continued service. Following this grant, Hamood directly holds 289,396 Class A shares and indirectly holds an additional 51,582 shares through AMHAM DH LLC.
Definitive Healthcare (DH) grants 189,190 RSUs to director Scott G. Stephenson
Definitive Healthcare (DH) director Scott G. Stephenson was granted 189,190 restricted stock units (RSUs) of Class A Common Stock. These RSUs will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting, conditional on his continued service. Following this grant, Stephenson directly holds 313,314 shares of Class A Common Stock.
Definitive Healthcare (DH) grants 189,190 RSUs to director Kathleen Winters
Definitive Healthcare Corp. (DH) reported that its director, Kathleen A. Winters, was granted 189,190 restricted stock units (RSUs) of Class A Common Stock. This equity grant, with no purchase price, increases her direct holdings to 308,982 shares. The RSUs are set to vest on the earlier of June 4, 2027, or the company’s next annual stockholders’ meeting, provided she continues her service.
Definitive Healthcare (DH) director awarded 189,190 RSUs, holdings now 315,984 shares
Definitive Healthcare Corp. director Chilukuri Sastry was granted 189,190 restricted stock units (RSUs) on June 4, 2026, increasing his direct holdings to 315,984 shares. These RSUs are a compensation award with no purchase price and will vest on the earlier of June 4, 2027, or the company's next annual meeting, provided Sastry continues his service. This transaction was reported in a Form 4 filing, detailing the award and its vesting conditions.
Definitive Healthcare (DH) investors approve equity plan share increase and pay
Definitive Healthcare Corp. shareholders approved all proposals at their 2026 annual meeting, including the election of three Class II directors, the ratification of Deloitte & Touche LLP as independent auditor, and an increase of 15,000,000 shares to the 2021 Equity Incentive Plan. They also gave non-binding advisory approval to the compensation of named executive officers. These decisions reflect broad investor support for the company's governance and compensation strategies.
Definitive Healthcare (DH) CFO has shares withheld to cover RSU tax bill
Definitive Healthcare Corp.'s CFO, Casey Heller, had 164,377 shares of Class A common stock withheld by the company to cover tax obligations arising from vested restricted stock units (RSUs). This transaction, valued at $0.99 per share, was a tax-withholding disposition rather than a market trade. Following this, Heller still directly holds a significant 1,841,476 shares of Class A common stock, maintaining a substantial equity position in the company.
Definitive Healthcare (DH) CEO sees 66,050 shares withheld for taxes
Definitive Healthcare (DH) CEO Kevin Coop had 66,050 shares of Class A Common Stock withheld at $0.99 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This transaction was a tax disposition, not an open-market sale, and represents a small portion of his total holdings of 5,012,822 Class A shares. The filing indicates a compensation-related event rather than a discretionary stock sale by the CEO.
Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights
Definitive Healthcare (Nasdaq: DH) has announced significant product enhancements to its data and analytics platform, aiming to provide organizations with a clearer view of the healthcare ecosystem. These updates include expanded medical claims coverage, a new integration with HubSpot, direct access to Healthcare Professional (HCP) data within Salesforce, and new AI search capabilities. The enhancements are designed to strengthen the company’s core data foundation and make insights more accessible, helping customers improve their sales, marketing, product development, and strategy with more confident decision-making.
Advent International holds 62,493,676 DH shares (NYSE: DH)
Advent International entities have reported beneficial ownership of 62,493,676 shares of Definitive Healthcare Corp.'s Class A common stock, representing 59.82% of the outstanding shares as of February 23, 2026. This ownership, detailed in a joint Schedule 13G/A filing, indicates shared voting and dispositive power among various Advent funds and related entities. The filing clarifies the control relationships and specific holdings of the Advent group, with the reported percentage based on 104,472,371 Class A shares outstanding.
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN) and Align Tech (ALGN)
This article summarizes analyst ratings for three healthcare companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN), and Align Tech (ALGN). Definitive Healthcare received a Hold rating from Canaccord Genuity, while Elanco Animal Health received a Buy rating from Evercore ISI, and Align Tech also secured a Buy rating from Evercore ISI. The report includes price targets and analyst consensus for each stock, highlighting potential upsides.
Definitive Healthcare (DH) Posts US$9.3 Million Q4 Loss Testing Profit Turnaround Hopes
Definitive Healthcare (DH) reported a Q4 net loss of US$9.3 million and a full-year net loss of US$138.9 million on US$241.5 million in revenue, according to its latest FY 2025 earnings report. While Q4 saw a narrowed loss per share compared to earlier in the fiscal year, the company continues to face significant losses and slow revenue growth. This performance places current optimism about future profitability and a low P/S ratio against historical widening losses and risks like tightening data privacy rules and industry consolidation.
Definitive Healthcare Reports Financial Results for First Quarter 2026
Definitive Healthcare announced its financial results for the first quarter of 2026, reporting revenue of $55.9 million and an Adjusted Net Income of $8.5 million, exceeding the high end of its guidance. The company highlighted improvements in retention rates and successful new customer acquisitions. Definitive Healthcare also provided its financial outlook for the second quarter and full year 2026, anticipating continued profitability and cash flow generation.
Definitive Healthcare posts $192M Q1 loss on $197M impairment
Definitive Healthcare (NASDAQ: DH) reported a Q1 2026 net loss of $(192.4) million, primarily due to a $197.2 million goodwill impairment charge, despite revenue falling 6% year-over-year to $55.9 million. The company achieved adjusted net income of $8.5 million and adjusted EBITDA of $15.3 million, demonstrating profitability on an adjusted basis and strong cash flow from operations. Definitive Healthcare also provided Q2 and full-year 2026 guidance, emphasizing continued focus on profitability and cash generation.
Massive goodwill hit but cash-positive quarter for Definitive Healthcare (DH)
Definitive Healthcare (DH) reported a Q1 2026 GAAP net loss of $192.4 million, significantly impacted by a $197.2 million goodwill impairment charge. Despite this, the company achieved positive non-GAAP profitability with Adjusted Net Income of $8.5 million and Adjusted EBITDA of $15.3 million, and generated $11.6 million in operating cash flow. Definitive Healthcare also provided 2026 full-year guidance expecting revenue between $220.0–$226.0 million and Adjusted EBITDA of $55.0–$59.0 million.
